PubRank

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Clinical Trial ID NCT01802632

PubWeight™ 32.52‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01802632

Top papers

Rank Title Journal Year PubWeight™‹?›
1 AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015 7.11
2 AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014 4.55
3 Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015 2.88
4 EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 2015 1.78
5 Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res 2015 1.43
6 Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016 1.32
7 Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res 2016 1.23
8 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
9 Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncol 2015 1.14
10 EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 2014 1.08
11 Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med 2014 1.06
12 Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 2014 0.95
13 Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. J Thorac Oncol 2015 0.93
14 Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther 2014 0.91
15 EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol 2016 0.90
16 Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med 2015 0.88
17 In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget 2015 0.88
18 Osimertinib making a breakthrough in lung cancer targeted therapy. Onco Targets Ther 2016 0.84
19 The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther 2016 0.84
20 Recent advances in personalized lung cancer medicine. Per Med 2014 0.82
21 Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 2014 0.80
22 NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget 2015 0.79
23 New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther 2016 0.75
Next 100